X CHIOME

Serial Number 79169641
Registration 5126156
706

Registration Progress

Application Filed
Apr 28, 2015
Under Examination
Approved for Publication
Nov 8, 2016
Published for Opposition
Nov 8, 2016
Registered
Jan 24, 2017

Trademark Image

X CHIOME

Basic Information

Serial Number
79169641
Registration Number
5126156
Filing Date
April 28, 2015
Registration Date
January 24, 2017
Published for Opposition
November 8, 2016
Drawing Code
3

Status Summary

Current Status
Active
Status Code
706
Status Date
Feb 6, 2023
Registration
Registered
Classes
005 042

Rights Holder

Chiome Bioscience Inc.

99
Address
3-12-1 Honmachi,
Shibuya-ku,
Tokyo 151-0071
JP

Ownership History

Chiome Bioscience Inc.

Original Applicant
99
Tokyo JP

Chiome Bioscience Inc.

Owner at Publication
99
Tokyo JP

Chiome Bioscience Inc.

Original Registrant
99
Tokyo JP

Legal Representation

Attorney
Jeffrey H. Handelsman

USPTO Deadlines

Next Deadline
396 days remaining
Section 71 Renewal Due (Principal Register 66a) (Based on registration date 20170124)
Due Date
January 24, 2027
Grace Period Ends
July 24, 2027

Application History

49 events
Date Code Type Description Documents
Oct 9, 2025 RNWL P INTERNATIONAL REGISTRATION RENEWED Loading...
Apr 18, 2025 NREP P NEW REPRESENTATIVE AT IB RECEIVED Loading...
Nov 12, 2023 INNP P PARTIAL INVALIDATION PROCESSED BY THE IB Loading...
Oct 11, 2023 INPS P PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB Loading...
Oct 11, 2023 INPC P INVALIDATION PROCESSED Loading...
Oct 6, 2023 INPR P PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED Loading...
Feb 6, 2023 NA71 E NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED Loading...
Feb 6, 2023 71AG O REGISTERED-SEC.71 ACCEPTED Loading...
Feb 3, 2023 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Jan 29, 2023 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Jan 19, 2023 ES71 I TEAS SECTION 71 RECEIVED Loading...
Jan 24, 2022 REM3 E COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED Loading...
Aug 4, 2017 OPNX P NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Loading...
May 12, 2017 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Apr 25, 2017 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Apr 25, 2017 FIMP P FINAL DISPOSITION PROCESSED Loading...
Apr 24, 2017 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Jan 24, 2017 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jan 6, 2017 OPNX P NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Loading...
Jan 4, 2017 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Jan 4, 2017 OPNR P NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Loading...
Nov 8, 2016 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Nov 8, 2016 PUBO A PUBLISHED FOR OPPOSITION Loading...
Oct 19, 2016 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Oct 19, 2016 OP2R P NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Loading...
Oct 19, 2016 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Oct 3, 2016 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Sep 24, 2016 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 20, 2016 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 19, 2016 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Sep 19, 2016 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Mar 17, 2016 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Mar 17, 2016 GNRT O NON-FINAL ACTION E-MAILED Loading...
Mar 17, 2016 CNRT R NON-FINAL ACTION WRITTEN Loading...
Feb 25, 2016 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 25, 2016 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 19, 2016 ALIE A ASSIGNED TO LIE Loading...
Feb 15, 2016 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Feb 15, 2016 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Feb 15, 2016 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Sep 4, 2015 RFNT P REFUSAL PROCESSED BY IB Loading...
Aug 14, 2015 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Aug 14, 2015 RFRR P REFUSAL PROCESSED BY MPU Loading...
Aug 14, 2015 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Aug 13, 2015 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 11, 2015 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Aug 8, 2015 DOCK D ASSIGNED TO EXAMINER Loading...
Aug 6, 2015 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 30, 2015 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 005
Monoclonal antibodies for medical [ or veterinary ] purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; peptides and proteins for medical [ or veterinary ] purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; [ biological and chemical preparations and reagents for medical or veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; ] medicines for human purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders [ ; medicines for dental purposes, namely, for infectious diseases, neurological diseases or inflammatory diseases; medicines for veterinary purposes, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; medicinal preparations, namely, for oncological, viral, infectious, endocrine, metabolic, neurological, cardiovascular, hematological, cardiopulmonary, respiratory, musculoskeletal, renal, hepatological, gastrointestinal, genitourinary, ophthalmic, dermatological, and immune system related diseases and disorders; living cells for manufacturing monoclonal antibodies used for medical purposes; cell lines for manufacturing monoclonal antibodies used for medical purposes; living cells for manufacturing monoclonal antibodies used for veterinary purposes; cell lines for manufacturing monoclonal antibodies used for veterinary purposes; biological tissue cultures for medical purposes, namely, for cultivating living cells or cell lines used for manufacturing monoclonal antibodies; dietary supplements for humans; nutritional supplements; dietary supplements for animals; dietetic foods, namely, protein adapted for medical purposes; dietetic beverages, namely, protein-based ready to drink beverages adapted for medical purposes; food for babies; powdered milk for babies; lacteal flour for babies; surgical implants comprised of living tissues; biological implants, namely, a vital processed human or animal connective tissue; disinfectants for hygiene purposes; sanitary sterilising preparations; biocides; preparations for destroying vermin ]
Class 042
Research, product development and quality control services in the field of proteins, antibodies, microorganisms and cells, and consultancy relating thereto; research and development services in the field of antibody technology; biomedical research services; [ design and development of medical technology; research and development in the field of biotechnology; ] pharmaceutical research and development [ ; conducting clinical trials for others in the field of pharmaceutical products; clinical trials for others; technical project studies in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical research in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; technical project planning in the field of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products; research and development of new products for others; design and development of computer software for use with medical technology; software design and development; providing temporary use of non-downloadable business software; rental of computer software; cloud computing featuring software used for development of monoclonal antibodies for medical or veterinary purposes and pharmaceutical products ]

Additional Information

Design Mark
The mark consists of a stylized "X" in white, within a blue square. Centered below the "X" is the term "CHIOME" in blue.
Color Claim
The color(s) blue and white is/are claimed as a feature of the mark.

Classification

International Classes
005 042